60[™] ERA CONGRESS MILAN & VIRTUAL JUNE 15-18, 2023

AMAZING NEPHROLOGY

INDUSTRY SYMPOSIA BOOKLET







Q

INDUSTRY SYMPOSIA BOOKLET

የ



2

	1		
10:00 11:00	ROOM	SESSION	SESSION TITLE
Boehringer Ingelheim Lilly	Space 1&2	ISS 1.1	KDIGO 2023 CKD Guideline: A Brave New World on the Evaluation, Prognostication, and Management of Kidney Disease
	Space 3&4	ISS 1.2	Genetic Screening in adult patients with end-stage kidney disease (ESKD)
UNOVARTIS Reimagining Medicine	Brown 3	ISS 1.3	C3G and IC-MPGN: From unmet needs to a collaborative approach towards improving outcomes
CHINOOK THERAPEUTICS	Brown 1&2	ISS 1.4	IgA Nephropathy: Where we are now and where we are going.
GSK	Amber 1&2	ISS 1.5	The window of opportunity in lupus nephritis: when to act to improve kidney outcomes?
sanofi	Amber 3&4	ISS 1.6	From first evidence to future therapy: Learnings from 2 decades of Fabry experience
CSL Vifor	Amber 5	ISS 1.7	Potassium control across the spectrum of CKD – optimising RAASi therapy and improving patient outcomes

13:30 14:30	ROOM	SESSION	SESSION TITLE
global rare diseases 🚱	Space 1&2	ISS 1.8	Beyond the kidney: new perspectives in inherited rare diseases
novo nordisk [®]	Space 3&4	ISS 1.9	GLP-1 RAs: towards an unmet need of people with T2D and CKD
Roche	Brown 3	ISS 1.10	Inspired to move mountains: emerging therapies in lupus nephritis
CSL Vifor	Brown 1&2	ISS 1.11	ANCA-associated vasculitis, the kidney and beyond
GSK	Amber 1&2	ISS 1.12	Anemia of CKD: time to take action
PHARMACOSMOS	Amber 3&4	ISS 1.13	Explore the latest hot topic within IV Iron in CKD and Heart Failure
AstraZeneca Rare Disease	Amber 5	ISS 1.14	What's new in the management of atypical haemolytic uraemic syndrome?
18:30 19:30	ROOM	SESSION	SESSION TITLE
JaFron	Amber 1&2	ISS 1.15	Adsorption in Chronic and Acute Clinical Settings
Otsuka	Amber 3&4	ISS 1.16	Lupus Nephritis: current challenges and novel treatment strategies.



Ŷ

INDUSTRY SYMPOSIA BOOKLET



10:00 11:00	ROOM	SESSION	SESSION TITLE
UNOVARTIS Reimagining Medicine	Space 1&2	ISS 2.1	Challenges and opportunities in IgA Nephropathy: Targeting the alternative complement pathway
sciarc	Space 3&4	ISS 2.2	Strengthening expertise in the treatment of chronic kidney disease
SCIENCE COLLECTED	Brown 3	ISS 2.3	Continuing lifesaving therapy in the cardiorenal patient: Practical guidance for managing hyperkalemia
SODI rare strength	Brown 1&2	ISS 2.4	Through different lenses: understanding the complexity of C3G and IC-MPGN
Caring for People's Health	Amber 1&2	ISS 2.5	Filling the gap by targeting the gut - First disease modifying treatment approved for IgAN
Asahi KASEI	Amber 3&4	ISS 2.6	Therapeutic Apheresis: Future Challenges
CSL Vifor	Amber 5	ISS 2.7	Patient-centered care in dialysis: let's tackle CKD-associated Pruritus

13:30 14:30	ROOM	SESSION	SESSION TITLE
	Space 1&2	ISS 2.8	This live activity is developed by Medtelligence and supported by an independent educational grant from CSL Vifor.
SCIENCE COLLECTED	Amber 1&2	ISS 2.9	Reshaping kidney care – Establishing the full potential of SGLT2 inhibitors as standard-of-care
TORAY	Brown 3	ISS 2.10	Immuno-nephrology: the dialysis membrane as a therapeutic strategy
FRESENIUS MEDICAL CARE	Brown 1&2	ISS 2.11	Hemocompatibility of dialyzers – How novel membranes may improve hemodialysis treatment
BAYER E R	Amber 1&2	ISS 2.12	Non-Steroidal MRAs: a new pillar of treatment for cardiorenal protection in CKD and T2D
Astellas	Amber 3&4	ISS 2.13	Complex pathophysiology and management in anaemia of CKD: is roxadustat the answer?
CSL Vifor	Amber 5	ISS 2.14	Ensuring a treatment continuum

የ



4



KDIGO 2023 CKD GUIDELINE: A Brave New World on the Evaluation, Prognostication, and Management of Kidney Disease

FRIDAY, JUNE 16 | 10AM-11AM SPACE 1&2 | MICO CONVENTION CENTRE ERA CONGRESS 2023 | MILAN, ITALY

> Chairperson ADEERA LEVIN | CANADA

Vision for the Guideline: Why now? PAUL STEVENS | UNITED KINGDOM

Evaluation of CKD: What's changed? RUMEYZA KAZANCIOGLU | TURKEY

Delaying CKD Progression and Complications: What's new? MAGDALENA MADERO | MEXICO









AMAZING NEPHROLOGY



GENETIC SCREENING IN ADULT PATIENTS WITH END-STAGE KIDNEY DISEASE (ESKD)



Prof. Pietro Manuel Ferraro Catholic University of the Sacred Heart of Rome, Italy



Prof. Nine Knoers



University Medical Centre Groningen, The Netherlands



Medizinische Genetik Mainz, Germany


Friday, 16 June 2023, 10:00-11:00, MiCo, Rooms 3 & 4

10:00-10:05	Welcome and introductions	Prof. Pietro Manuel Fe
10:05-10:20	Clinical utility of genetic testing in adult patients with CKD and ESKD	Prof. Nine Knoers
10:20-10:35	Overcoming the challenges of and barriers to genetic screening in routine clinical practice	Prof. Carsten Bergman
10:35-10:50	How to successfully implement a screening programme for a rare genetic condition	Prof. Pietro Manuel Fe
10:50-11:00	Panel discussion and summary	All

Chronic Kidney Disease (CKD). The European Renal Association (ERA) assumes no responsibility for the information published in this document. For healthcare professionals only. You will need to be registered for the congress to attend. Registration conditions differ internationally; please refer to your local prescribing information for further information. To report adverse events, please refer to your local reporting guidelines. © 2023 Alnylam Netherlands B.V. All rights reserved. April 2023 PH1-CEMEA-00113. This is a non-promotional meeting, funded and organised by Alnylam.



Visit alnylamconnect.eu to sign up to receive further information about PH1 from Alnylam.







Novartis-sponsored satellite symposium on C3 glomerulopathy

ERA 2023

C3G and IC-MPGN: From unmet needs to a collaborative approach towards improving outcomes



Welcome from the Chair

It is our great pleasure to welcome you to the Novartis-sponsored symposium at this year's **60th European Renal Association (ERA) Congress 2023.**

The symposium entitled **C3G** and **IC-MPGN:** From unmet needs to a collaborative approach towards improving outcomes will examine the current state of evidence and clinical management in C3G and IC-MPGN and discuss about the CompCure Association and the European Registry for C3G and IC-MPGN.

Our expert faculty will explore these topics via clinical case presentations and engaging panel discussions, and we warmly encourage your active participation during the Q and A session. We hope you enjoy what will be an interesting and informative session.

Fadi Fakhouri

(Chair for C3G and IC-MPGN symposium)

Centre Hospitalier Universitaire Vaudois and Université de Lausanne, Lausanne, Switzerland

C3G and IC-MPGN: From unmet needs to a collaborative approach towards improving outcomes

16 June 2023 | 10:00–11:00 (CET) | ERA Congress 2023 MiCo – Milano Convention Centre, Milan, Italy

Room number: Brown 3, Level 2

- 10:00 Welcome and introduction Chair: Fadi Fakhouri
- 10:05 Current state of evidence in C3G and IC-MPGN and impact of uncertainties on clinical management Fadi Fakhouri
- 10:25 The CompCure Association committed to improving outcomes in C3G and IC-MPGN Marianne Silkjaer-Nielsen
- 10:30 A comprehensive European Registry for C3G and IC-MPGN Marianne Silkjaer-Nielsen & Franz Schaefer
- **10:45** Audience Q and A All faculty (moderated by Chair)
- 10:58 Closing remarks Chair: Fadi Fakhouri

Faculty







Novartis Pharma AG (© 2023 Novartis Pharma AG, CH-4002 Basel, Switzerland FUSE MLRID: 276802 | Approval April 2023 P3 approval code: 10230319000

UNOVARTIS | Reimagining Medicine

 Fadi Fakhouri (Chair)
 Mar

 Centre Hospitalier Universitaire Vaudois and
 Co

 Université de Lausanne, Lausanne, Switzerland
 Co

Marianne Silkjaer-Nielsen CompCure, Aarhus, Denmark Franz Schaefer University Children's Hospital Heidelberg, Heidelberg, Germany

60TH ANNUAL EUROPEAN RENAL ASSOCIATION CONGRESS

Chinook Therapeutics: IgA Nephropathy: where we are now and where we are going.

PRESENTED BY:



Dana Rizk, мо

Professor of Medicine, Nephrology Division The Anupam Agarwal Endowed Scholar in Nephrology Director of Clinical Trials Research, Nephrology Division Medical Director of Clinical Trials Administrative Office University of Alabama at Birmingham



Rosanna Coppo, MD, FERA

Fondazione Ricerca Molinette

Past Director of Nephrology, Dialysis and Transplantation, Regina Margherita Children's Hospital, Turin, Italy

International IgAN Network Research Group


SUPPORTED BY



The Exhibitor Spotlight is not a Continuing Education (CE) activity Friday June 16, 2023 10:00 - 11:00 am CEST

MiCo – Milano Convention Centre

Brown Hall 1&2





7



For Healthcare Professionals only

The window of opportunity in lupus nephritis: when to act to improve kidney outcomes?

16th June, **10:00–11:00 CEST** (UTC +2)

Room Amber 1 & 2, MiCo Convention Centre, Milan, Italy



Professor Liz Lightstone, *UK*, will chair expert discussions of clinical case studies centred around lupus nephritis management




Forward thinking in the management of lupus nephritis **Dr Lucio Manenti**, *Italy*



Can we meet the challenge to improve kidney outcomes in lupus nephritis? **Professor Onno Teng**, *the Netherlands*

The event was duly communicated to the competent AIFA office, within the terms and in the manner established by art. 124, co. 1 of Legislative Decree 219/06 and subsequent implementing provisions, and complies with the requirements established by the current Farmindustria Code of Conduct.

An industry symposium sponsored and organised by GSK. GSK products will be discussed. Prescribing Information for all GSK products discussed will be available at the event and the GSK booth.





of Fabry experience

Friday 16th June 2023

10:00-11:00 (CET)

Room Amber 3&4



AGENDA **FROM FIRST EVIDENCE** Welcome and introduction Antonio Pisani **TO FUTURE THERAPY:** Department of Nephrology, University Federico II, Italy Learnings from 2 decades More than 20 years of the patient-centered Fabry **Alberto Ortiz** Registry: Real-world scientific evidence advancing Fundación Jiménez Díaz, Spain Fabry disease expertise and better informing the Fabry community Cleared podocytes and normal kidney function in Camilla Tøndel

classical Fabry males 15 years after start of enzyme replacement therapy at young age

Future oral therapies focusing on glucosylceramide synthase inhibition: Evidence from clinical programs

Q&A and panel discussion

All

University of Bergen and Haukeland University Hospital, Norway

Patrick Deegan Cambridge University Hospitals NHS Foundation Trust. UK



Prof Antonio Pisani Department of Nephrology, University Federico II, Italy



Prof Alberto Ortiz Health Research Institute of the Jiménez Díaz Foundation, Spain



Prof Camilla Tøndel University of Bergen and Haukeland University Hospital, Norway



Dr Patrick Deegan Cambridge University Hospitals NHS Foundation Trust, UK



sanofi



EBAC ACCREDITED EDUCATIONAL PROGRAMME DURING THE 60th ERA CONGRESS

POTASSIUM CONTROL ACROSS THE SPECTRUM OF CKD – OPTIMISING RAASI THERAPY AND IMPROVING PATIENT OUTCOMES

FRIDAY, JUNE 16, 2023 10:00-11:00 CEST AMBER 5 ROOM



Please scan this QR code to complete the EBAC evaluation form Chair: Francesca Mallamaci, Reggio Calabria, Italy

10:00-10:03

Welcome and introduction Francesca Mallamaci, Reggio Calabria, Italy

10:03–10:18 Hyperkalaemia – still an issue in the management of CKD? Maria C. Haller, Linz, Austria

10:18-10:33

Potassium control across the spectrum of CKD – practical guidance and novel therapeutic options Patrick Rossignol, Monaco, Monaco

10:33-10:48

Optimising RAAS inhibition in patients with CKD and comorbidities – current guidelines and lessons from recent trials Charles J. Ferro, Birmingham, UK

10:48-10:58

Interactive panel discussion All faculty

10:58-11:00

Concluding comments Francesca Mallamaci, Reggio Calabria, Italy

EDUCATIONAL OBJECTIVES:

- Describe prognostic implications and dynamics of serum potassium in patients with chronic kidney disease (CKD) requiring or not requiring dialysis
- Recognise the importance of hyperkalaemia as a threat to patient safety and as a barrier to optimal reninangiotensin-aldosterone system inhibitor (RAASi) therapy in patients with CKD
- Highlight the need for close monitoring of serum potassium in patients with CKD
- Evaluate the role of novel potassium binders in optimising the use of RAASi therapy in patients with CKD and other risk factors for hyperkalaemia
- Discuss the cardiorenal benefits of RAASi therapy and current guidelines for their use in patients with CKD
 and comorbidities such as heart failure, resistant hypertension and type 2 diabetes





MedEd



11



CHIESI INDUSTRY SYMPOSIUM BEYOND THE KIDNEY: new perspectives in inherited rare diseases

The symposium will be a combined one between Nephropathic Cystinosis (NC) and Fabry Disease (FD), providing a patient centric overview of the current unmet needs through clinical cases and new data.

AGENDA

Welcome and Introduction - C. Wanner

The importance of patients' perspective for the assessment of symptoms: the unmet needs in FD from a patients' perspective. Results of the patients'survey - *R. Torra*

Adult patients' management in NC: clinical case reports - *A. Servais*

How to update the optimal monitoring in FD considering the new data - *A. Pisani*

Closing & remarks - C. Wanner

Chairman and Moderator:



Christoph Wanner (Wurzburg, Germany)

Speakers:



Roser Torra (Barcelona, Spain)



Aude Servais (Paris, France)

Antonio Pisani (Naples, Italy)



AMAZING NEPHROLOGY

ERA 2023 Novo Nordisk symposium

GLP-1 RAs: towards an unmet need of people with T2D and CKD

Friday, June 16th, 2023, 13:30-14:30 (CEST) MiCo – Milano Convention Centre, Milan, Italy

Dear colleagues,

On behalf of Novo Nordisk, I am delighted to invite you to the Novo Nordisk industry symposium at ERA 2023 entitled "GLP-1 RAs: towards an unmet need of people with T2D and CKD". The ERA Annual Symposium will be held face-to-face in Milan on June 16th at 13:30-14:30 (CEST) and broadcasted online.

Chronic kidney disease (CKD) is a common complication of Type 2 Diabetes (T2D), presence of which also significantly amplifies the risk of cardiovascular diseases (CVD). The current medical guidelines emphasize on a holistic approach, to consider CKD and CVD status from the beginning while treating people with T2D.

In this symposium, with our world-renowned faculty, we aim to highlight unmet medical needs for management of CKD in people with T2D. We will be discussing about the current landscape of the treatment options available for the people with CKD and T2D and touch base on the evolution of medical guidelines over time. With a focus on GLP-1 RAs, we will be discussing how this class of medications are increasingly being recognized for their potential for the treatment of people with T2D and CKD. We will also be presenting the baseline characteristic data of the people who were the part of the FLOW clinical trial, the first dedicated kidney outcomes trial with a GLP-1 RA.

This session will last 60 minutes and will consist of a mix of short presentations, panel discussion and Q&A. During the Q&A, you will have the opportunity to ask guestions and engage with the expert speakers.

I really look forward to welcoming you to this informative and interactive symposium experience.

To know more about the symposium, please visit Novo Nordisk Science Hub.

Kind Regards,

Rubdeep Singh Bindra

Rubdeep Singh Bindra Global Medical Director Semaglutide Diabetes, Global Medical Affairs Novo Nordisk

03 mins	Welcome and Int Chair: Peter Rossi			
15 mins	What are we looking for in treatment of people with CKD and T2D? (including roundtable discussion) Adeera Levin (CA)			
15 mins	Clinical and treat Roland Schmieder		D and T2D (including round	dtable discussion)
15 mins		uding roundtable disc	P-1 RA kidney outcomes tria ussion)	l will add to current
10 mins	Audience Q&A All speakers			
02 mins	Closing remarks Peter Rossing (DK			
Steno Diabetes	sing MD, DMSc Center Copenhagen, enmark	Adeera Levin, MD, FRCPC, FCAHS, OC University of British Columbia, Canada	Roland Schmieder, MD, FACC, FACP, FASN, FESC Friedrich Alexander University Erlangen/Nürnberg, Germany	Hiddo J.L. Heerspink University Medical Center Groningen, Netherlands



13

INDUSTRY SYMPOSIUM at ERA 2023



Inspired to move mountains: emerging therapies in lupus nephritis

Friday 16th June, 13:30–14:30 CEST, Brown 3, MiCo, Milan

13:30-13:35	Welcome and introduction	Gabriella Luisa Moroni
13:35-13:50	Reaching base camp: B-cell depletion	Rachel Jones
13:50-14:05	One step at a time: complement inhibition	Marina Vivarelli
14:05-14:20	Climbing to the peak: from theory to clinical reality	Liz Lightstone
14:20-14:30	Q&A and close	All



RocheNephrology

INSPIRED BY M & M W

This symposium is not intended for physicians practicing in the US Veeva number: M-XX-00012844 Date of preparation: April 2023



14

An Industry Symposium held during the 60th ERA Congress Milan and virtual Congress

ANCA-associated vasculitis, the kidney and beyond

Friday 16 June 2023 13.30-14.30 CET Brown 1&2




Agenda

- 13.30 Welcome and introduction Chair - Dr. Andreas Kronbichler, Addenbrooke's Hospital; University of Cambridge, Cambridge, UK
- **13.35** Targeting unmet needs in clinical practice Prof. Federico Alberici, Università degli Studi di Brescia; ASST Spedali Civili, Brescia, Italy
- 13.55 Ongoing challenges in ANCA-associated vasculitis – can we do better? Dr. Silke Brix, Manchester University NHS Foundation Trust and Division of Cell Matrix Biology and Regenerative Medicine, University of Manchester, UK
- 14.10 Q&A Chair - Dr. Andreas Kronbichler
- 14.30 Close Chair - Dr. Andreas Kronbichler

MED-HQ-AVA-2300005 Date of approval March 2023









13:30–13:35 Welcome and introduction Lucia Del Vecchio

13:35–13:55 Anemia of CKD: common, yet under-recognised? Ciro Esposito

13:55–14:10 Patient-centred care to optimise current treatment Ciro Esposito and Frank Strutz

14:10–14:25 Latest innovations in patient care Frank Strutz

14:25–14:30 Summary and close Lucia Del Vecchio

Includes insights from Angela Watt, a retired renal nurse and patient living with anemia of CKD Audience Q&A will be held at the end of each presentation



Lucia Del Vecchio (Chair)

Department of Nephrology and Dialysis at Sant'Anna Hospital, Como, Italy



Ciro Esposito

Nephrology and Dialysis Unit at ICS Maugeri, University of Pavia, Italy



Frank Strutz

Kidney Centre Wiesbaden-Rheumatology and DKD Helios Hospital Wiesbaden, Germany

NX-GBL-DPR-ADVT-230003 | May 2023

© 2023 GSK group of companies. All rights reserved. GlaxoSmithKline UK Limited registered in England and Wales No 4310159. Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.



PHARMACOSMOS LUNCH SYMPOSIUM

Explore the latest hot topic within IV Iron in CKD and Heart Failure

Chairman: Professor Nephrologist Loreto Gesualdo, Italy

TOPICS AND SPEAKERS:

Professor Nephrologist Philip Kalra, United Kingdom The value of anaemia management in a cardiorenal clinic

Cardiologist Fozia Ahmed, United Kingdom IRONMAN Trial Design - The emerging role of IV iron to reduce cardiovascular risk, particularly the risk of hospitalisation for heart failure

Meet the experts at this lunch symposium and gain new insights that will inspire you in your clinical practice.

This symposium will also be available virtually during and after the congress - more information will follow.

60° ERA CONGRESS MLAN & VIRTUAL JUNE 15-18. 2023 ERA 2023, Milan Date: Friday June 16th, Time: 13.30 pm - 14.30 pm Venue: Milano Convention Centre Viale Eginardo, 7, GATE 2, 20149 Milan, Italy Amber 3&4

FREE LUNCH will be available at the symposium

PHARMACOSMOS



AMAZING NEPHROLOGY

17



We cordially invite you to the Alexion, AstraZeneca Rare Disease Satellite Symposium at the 60th Annual Scientific Meeting of The European Renal Association

What's new in the management of atypical Haemolytic Uraemic Syndrome?

Friday 16 June 2023, 13:30–14:30 (CET) Room Amber 5, MiCo - Milano Convention Center and Virtual

Programme	Faculty	
Chair's welcome and introduction Overview of management approaches to aHUS	Prof. Manuel Praga Madrid, Spain	
Clinical and real-world experience with currently approved treatments for aHUS	Dr Anuja Java St. Louis, USA	X
Recognition and management of aHUS in the presence of associated clinical conditions or events	Dr Sjoerd Timmermans Maastricht, The Netherlands	X
Q&A session	All speakers	
Closing remarks	All speakers	12

This symposium is fully funded and organised by Alexion, AstraZeneca Rare Disease. Alexion, AstraZeneca Rare Disease products may be discussed this event. This event is intended for healthcare professionals only. Information presented at this industry-sponsored symposium is not necessarily endorsed by ERA.

The content of each presentation was prepared independently by the speaker, with limited feedback from Alexion, AstraZeneca Rare Disease. The views expressed by the speakers are not made on behalf of Alexion, AstraZeneca Rare Disease and do not necessarily represent the position of the company.



Alexion Pharmaceuticals, Inc., 121 Seaport Boulevard, Boston, MA 02210 Alexion, AstraZeneca Rare Disease document number: M/INT/ULT-a/0034



afronBiomedica





Hemoadsorption in Chronic and Acute Clinical Settings



Chair: Claudo Ronco Italy





Speaker: Vincenzo Panichi Italy



Jinjun Chen China

- Improving Uremic Complications: How can Hemoadsorption Help
- Hemoadsorption in Septic Patients: Clinical Experience ٠
- DPMAS in ACLF. The PADSTONE study on 1300 Patients •

Time: 18:30-19:30 CET Date: June 16th 2023 Room: AMBER 1&2



SYMPOSIUM

LUPUS NEPHRITIS:

current challenges and novel treatment strategies.

Friday June 16th, 2023 18:30 - 19:30 CEST

Otsuka

Milan, Allianz MiCo, Amber 3 & 4

18:30 - 18:35	Introduction Prof. Y. K. O. Teng
18:35 - 18:55	Current treatment: what are the unmet needs? Prof. L. Arnaud
18:55 - 19:15	New therapeutic options: is a paradigm change possible? Prof. G. L. Moroni
19:15 - 19:30	Interactive survey and live Q&A Prof. L. Arnaud, Prof. G. L. Moroni, Prof. Y. K. O. Teng
	Prof. Y. K. Onno Teng - <i>Chair</i>

Leids Universitair Medisch Centrum (LUMC), NL

Prof. Laurent Arnaud Centre Hospitalier Universitaire de Strasbourg, FR

Prof. Gabriella Luisa Moroni Department of Biomedical Sciences Humanitas University, Milan, IT





Novartis-sponsored satellite symposium on IgA nephropathy ERA 2023

Challenges and opportunities in IgA nephropathy: Targeting the alternative complement pathway



It is our great pleasure to welcome you to the Novartis-sponsored symposium at this year's 60th European Renal Association (ERA) Congress 2023.

The symposium entitled **Challenges and opportunities in IgA Nephropathy: Targeting the alternative complement pathway** will examine the heterogenous nature of IgAN, current management recommendations and their limitations. It will also highlight the role of the alternative complement pathway in the pathogenesis of IgAN.

Our expert faculty will explore these topics via clinical case presentations and engaging panel discussions, and we warmly encourage your active participation during the Q and A session. We hope you enjoy what will be an interesting and informative session.

Jürgen Fl	oege	
(Co-Chair	for IgANs	ymposiun

Richard Lafayette

RWTH Aachen University, Aachen, Germany Stanford University Medic

(Co-Chair for IgAN symposium) Stanford University Medical Center, California, United States

Challenges and opportunities in IgA nephropathy: Targeting the alternative complement pathway

17 June 2023 | 10:00–11:00 (CET) | ERA Congress 2023 MiCo – Milano Convention Centre, Milan, Italy

Room number: Space 1 and 2, Level 0

- 10:00 Welcome and introduction Co-Chairs: Jürgen Floege and Richard Lafayette
- 10:05 The challenges with IgAN in clinical practice today Smeeta Sinha
- **10:25** Complement in IgAN: A key driver of the pathogenesis? Sydney Tang
- **10:45** Audience Q and A All faculty (moderated by the Chairs)
- 10:58 Closing remarks Co-Chairs: Jürgen Floege and Richard Lafayette

Faculty



Jürgen Floege

(Co-Chair)

RWTH Aachen University.

Aachen, Germany



(Co-Chair)

Stanford University Medical Center.

California, United States



Sudan Sudan

Smeeta Sinha Salford Royal NHS Foundation Trust, Salford, United Kingdom University of Manchester, Manchester, United Kingdom

Novartis Pharma AG © 2023 Novartis Pharma AG, CH-4002 Basel, Switzerland FUSE MLRID: 276802 | Approval April 2023 P3 approval code: 10230319000

UNOVARTIS | Reimagining Medicine





ERA Congress 2023, Milan and virtual

Saturday, 17 June 2023 | 10:00 – 11:00 CEST Milano Convention Centre, Space 3&4 and virtual

- Chair: Malyszko, Jolanta (Warsaw, Poland)
- **10:00 10:05**Welcome & IntroductionMalyszko, Jolanta (Warsaw, Poland)
- 10:05 10:20 Challenges and opportunities in the treatment in CKD Wheeler, David (London, UK)
- 10:20 10:35 Improving clinical outcomes in CKD: novel approaches Pontremoli, Roberto (Genoa, Italy)

- 10:35 10:50 Commentary: Practical considerations for CKD management Borg, Rikke (Roskilde, Denmark)
- **10:50 11:00 Discussion & Closure** Malyszko, Jolanta (Warsaw, Poland)

Program of the industry session



Supported by a Medical Education Grant from Boehringer Ingelheim and Lilly Alliance

Sciarc GmbH I Schorner Str. 1a I 82065 Baierbrunn, Germany I <u>www.sciarc.de</u>

SCIENCE COLLECTED

IORN

Continuing lifesaving therapy in the cardiorenal patient: **Practical guidance for** managing hyperkalemia

Saturday, 17th June 2023, 10:00 - 11:00 CEST MiCo South - Level +2



James Burton (Chair) University of Leicester UK



Manish Sood University of Ottawa Canada




University of Manitoba Canada





Agenda

Time	Session	Speaker
10:00 - 10:05	Welcome and introductions	James Burton
10:05 – 10:15	Catch-22 – hyperkalemia and RAASi	Manish Sood
10:15 – 10:45	Reaching consensus – Optimising care for cardiorenal patients <i>Panel Discussion</i>	All faculty
10:45 - 10:55	Panel discussion and Q&A	All faculty
10:55 – 11:00	Closing remarks	James Burton







ERA hybrid congress 2023 Milan, Italy & virtual 15–18 June 2023

Through different lenses:

understanding the complexity of C3G and IC-MPGN

Saturday, 17 June 2023 10:00-11:00 CEST



A multidisciplinary expert panel featuring...


Chair's welcome Fernando Caravaca-Fontán, Spain

Beneath the surface: the heterogeneous pathophysiology of C3G/IC-MPGN Marina Noris, Italy

Demystifying the diagnostic pathway and disease progression in C3G/IC-MPGN Fernando Caravaca-Fontán, Spain The patient voice: the uncertainty of living with severe progressive kidney disease Antonia King, Germany

Closing remarks and Q&A: Can we redefine the future of patient management in C3G/IC-MPGN? All faculty Chair: Fernando Caravaca-Fontán, Spain





Sobi is a trademark of Swedish Orphan Blovitrum AB (pub) B0203 Swedish Orphan Blovitrum AB (pub) – All rights reserved The medical education session is intended for healthcare professionals Organised and funded by Sobi™ Swedish Orphan Blovitrum AB (pub) Ef 112 76 Stockholm, Sweden www.sobi.com





24

Asahi KASEI

Therapeutic Apheresis: FUTURE CHALLENGES



AZING NEPHROLOGY

25

June 17th - 10:00-11:00 🖾

Room Amber 3&4

Chairman Dr. Emanuela de Pascale Napoli, Italy Co-Chairman Prof. Reinhard Klingel Cologne, Germany



Villingen-Schwenningen, Germany

PATIENT-CENTRED CARE IN DIALYSIS: LET'S TACKLE CKD-ASSOCIATED PRURITUS

Saturday 17 June 2023, 10.00–11.00 CEST Room Amber 5, MiCo – Milano Convention Centre, Italy

Dear Colleague,

It is my pleasure to invite you to this CSL Vifor-sponsored educational symposium, entitled 'Patient-centred care in dialysis: let's tackle CKD-associated Pruritus', as part of the 60th ERA congress in Milan.

CKD-associated Pruritus is a condition that significantly impacts the quality of life and medical outcomes of patients receiving haemodialysis. Despite this, CKD-associated Pruritus is under-reported, under-recognised and options for its treatment have previously been suboptimal. However, the increasing recognition of symptom-oriented care and the changing treatment landscape for CKD-associated Pruritus provides new opportunities for nephrologists to support patients in their quest for an improved quality of life.

The expert faculty will provide an overview of CKD-associated Pruritus and share their experience of its management. The symposium will conclude with a live Q&A session, providing an opportunity for audience questions be addressed.

We look forward to welcoming you to this exciting, educational symposium.

Professor Lucio Manenti Chair

VIFOR FRESENIUS MEDICAL CARE 😴

Vifor Fresenius Medical Care Renal Pharma Ltd has fully sponsored this symposium and worked with the speakers on choice of topic and content. Payment has been made to the congress organiser to hold the symposium. Approval conditions for drugs mentioned during the symposium may vary from country to country. Before prescribing, always refer to the local SmPCs. Materials related to this product are intended for Healthcare Professionals from Europe. The ERA assumes no responsibility for the information published in this document.

PROGRAMME

Welcome and introduction Lucio Manenti, Italy (Chair)

An insight into the burden and prevalence of CKD-associated Pruritus Antoine Lanot, France

An opportunity to improve CKD-associated Pruritus: sharing clinical experience of difelikefalin Leonie Kraft, Germany and Joerg Latus, Germany

A changing landscape for the treatment of CKD-associated Pruritus Lucio Manenti, Italy (Chair)

Audience Q&A

Summary and meeting close Lucio Manenti, Italy (Chair)



CSL Vifor

Date of preparation: April 2023 HQ-DFK-230047 © 2023 Vifor Fresenius Medical Care Renal Pharma Ltd. All rights reserved



Achieving Success in IgAN & FSGS: Expert Insights on Current and Future Therapies Saturday, June 17, 2023 | 13:30 – 14:30 CEST

Milan Convention Center, Level 0 – Space 1 & 2

CME-ACCREDITED SYMPOSIUM TO BE HELD DURING ERA 2023

Learn about novel mechanisms and emerging data in IgAN and FSGS.

After attending this symposium, attendees will be able to:

- Improve their diagnosis of immunoglobulin A nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS)
- Discuss current treatment considerations of IgAN and FSGS
- Develop treatment plans to lower proteinuria in patients with IgAN and FSGS
- Review emerging treatment approaches for IgAN and FSGS
- Interpret emerging clinical trial data in IgAN and FSGS

CHAIR:

Siân Griffin, MD, PhD Consultant Nephrologist Honorary Professor, Cardiff University Department of Nephrology and Transplantation University Hospital of Wales Cardiff, United Kingdom

FACULTY:

Jürgen Floege, MD Director, RWTH Aachen University Hospital Aachen, Germany

Loreto Gesualdo, MD, FERA Full Professor of Nephrology University of Bari Aldo Moro Bari, Italy

The ERA assumes no responsibility for the information published in this document.

This activity is supported by an independent educational grant from CSL Vifor. The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting *AMA PRA Category 1 Credits*TM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.









SCIENCE COLLECTED RESHAPING KIDNEY CARE

ESTABLISHING THE FULL POTENTIAL OF SGLT2 INHIBITORS AS STANDARD-OF-CARE

SATURDAY, 17TH JUNE 2023 | 13:30-14:30 MICO SOUTH | LEVEL 0 | ROOM SPACE 3&4

1			(
	C)	
		-	-

Kieran McCafferty (Chair) Barts Health NHS Trust London, UK **David Cherney** University of Toronto, Canada



AGENDA

Duration	Session	Speaker
13:30 – 13:35	Welcome and introductions	Kieran McCafferty
13:35 – 13:45	From early to late in CKD – nephrologists and their role before secondary care	Kieran McCafferty
13:45 – 14:00	Time to make flozination a standard-of-care	David Cherney
14:00 – 14:15	Overcoming barriers to the use of SGLT2 inhibitors – ILearnings from our journey so far	Paola Fioretto
14:15 – 14:25	Panel discussion and Q&A	All faculty
14:25 – 14:30	Closing remarks	Kieran McCafferty



This symposium is accredited for 1 CME credit by Royal College of Physicians



28





LUNCH SYMPOSIUM 17 June | 13:30-14:30 | BROWN Hall 3

Immuno-nephrology: the dialysis membrane as a therapeutic strategy

G. Castellano (Milan, Italy) and I. Masakane (Yamagata, Japan)

- **13:30-13:48Transplant-waitlisted patients and DGF: role of PMMA membrane**
G. Castellano (Milan, Italy)
- **13:48-14:06** New frontier of anti-thrombogenic membrane: technology and clinical applications *P. Rieu (Reims, France)*
- 14:06-14:24Inhibiting complement activation in septic AKI: why consider PMMA-based dialysisV. Cantaluppi (Novara, Italy)

14:24-14:30 Discussion


Supported by: Toray Medical Co.,Ltd.



29







60th ERA Congress, Milan and virtual Hemocompatibility of dialyzers – How novel membranes may improve hemodialysis treatment

Industry Symposium

Saturday, June 17th 13:30–14:30 Room: Brown 1 & 2 and live stream

Chair:

Prof. Dr. Alberto Ortiz, University of Madrid, Spain

Clinical expectations on hemocompatibility of dialyzers Prof. Dr. Alberto Ortiz, Spain

Inflammation – the fire that burns within Prof. Dr. Peter Stenvinkel, Sweden **Biocompatibility of dialyzer membranes: relevance in current clinical practice** Assoc. Prof. Dr. Muriel Grooteman, the Netherlands

From bench to bedside – the development of a novel hydrolayer membrane Ass. Prof. Dr. Fatih Kircelli, GMO Fresenius Medical Care, Germany

Head office: Fresenius Medical Care Deutschland GmbH 61346 Bad Homburg v.d.H. · Germany · Phone: +49 (0) 6172-609-0 www.freseniusmedicalcare.com For more information, please visit us at booth #B.700



Industry session on the occasion of the European Renal Association congress 2023

As an expert in this area of clinical practice, we are delighted to invite you to participate in the Bayer symposium titled

Non-steroidal MRAs: A new pillar of treatment for cardiorenal protection in CKD and T2D

Saturday 17 June; 13:30–14:30

mprehensive and I	ers a unique opportunity to gain an overview of the most recent guideline updates related nolistic approach to the patient management. To discuss the use of the 'pillar approach inclice based on expert experience. To highlight the relevance of the urgency to treat CP	i' to manage CKD in T2D and how to use
:30 – 13:35	Welcome and introductions	Guiseppe Grandaliano
:35 – 13:45	Nonsteroidal MRAs as part of the comprehensive approach to CKD: Guidelines update	Beatriz Fernandez Fernandez
:45 – 14:00	Pillar approach for the treatment of CKD in T2D: treat early to help prevent further CV and renal damage	Christoph Wanner
:00 – 14:15	Beyond CKD progression: cardiorenal protection across the spectrum of CKD in patients with T2D	Rajiv Agarwal
:15 – 14:30	Q&A and closing	All



Astellas-sponsored symposium

Complex pathophysiology and management in anaemia of CKD: is roxadustat the answer? Simplicity through innovation

Saturday 17 June 2023 | 13:30-14:30 CEST | Amber 3 & 4, Level +2, MiCo

Faculty:



Chairperson: Professor Mario Cozzolino University of Milan, Italy



Professor Denis Fouque University Claude Bernard, Lyon, France



Professor Roberto Minutolo University of Campania, Naples, Italy _____



Dr Monica Gross DaVita Falkensee, Germany

Time	Session	Speaker
13:30–13:35	Welcome and introductions	Professor Mario Cozzolino
13:35–13:45	The complexities of anaemia of CKD: disease burden, pathophysiology and management	Professor Denis Fouque
13:45–14:10	Roxadustat and the impact of a physiological approach to treatment	Professor Roberto Minutolo
14:10-14:25	Roxadustat in the real-world: the patient experience	Dr Monica Gross
14:25–14:30	Q&A and meeting close	All

The symptoms of anaemia can be debilitating for our patients and effective management is key to improving quality of life and reducing the risk of adverse outcomes of anaemia in this challenging population.

This symposium will draw on the experience of the faculty to explore the clinical evidence, real-world experience, practicalities and potential of roxadustat, the first HIF-prolyl hydroxylase inhibitor to be approved for the treatment of adult patients with anaemia of CKD.

Professor Mario Cozzolino

CKD, chronic kidney disease; HIF, hypoxia-inducible factor.

This symposium is sponsored by Astellas and is intended for healthcare professionals only. This symposium contains information about Astellas products.

MAT-IT-EVZ-2023-00032 | Date of prep: April 2023 | Expiry date: July 2023. © 2023 Astellas Pharma Inc. or its affiliates. All trademarks are the property of their respective owners.







Ensuring a **treatment continuum** for CKD-MBD

Saturday 17 June 2023, 13.30-14.30 CEST

Room Amber 5 MiCo - Milano Convention Centre, Italy

Dear Colleague,

It is my pleasure to invite you to this CSL Vifor-sponsored educational symposium, entitled '**Ensuring a treatment continuum for CKD-MBD**', as part of the 60th ERA congress in Milan.

The chronic kidney disease-mineral bone disorder (CKD-MBD) continuum describes a spectrum of conditions resulting from progressive deterioration of hormonal and mineral homeostasis, and subsequent alterations in laboratory parameters, including serum phosphate, calcium, parathyroid hormone and vitamin D. CKD-MBD can affect patients across all stages of CKD, and may lead to severe clinical outcomes, including vascular calcification and increased mortality.

During this informative symposium, the expert faculty will introduce a holistic approach to managing CKD-MBD, emphasising the need for effective treatment and quality patient care from the early, non-dialysis stages of CKD to stage 5 CKD. Specifically, the discussions will focus on the management of secondary hyperparathyroidism (SHPT) and hyperphosphataemia.

The symposium will conclude with a live Q&A session, during which we will address questions from the audience.

This year, we are pleased to welcome both an in-person and virtual audience to our exciting symposium, bringing together colleagues from across the globe to discuss the importance of effective management across the CKD-MBD continuum.

Smeeta Sinha Chair

The ERA assumes no responsibility for the information published in this document

Vifor Fresenius Medical Care Renal Pharma Ltd has fully sponsored this symposium and worked with the speakers on choice of topic and content. Payment has been made to the congress organiser to hold the symposium.

Approval conditions for drugs mentioned during the symposium may vary from country to country. Before prescribing, always refer to the local SmPCs. Materials related to this product are intended for healthcare professionals from Europe.

Programme

- 13.30 Welcome and introduction to vascular calcification Smeeta Sinha, UK (Chair)
- 13.45 Importance of early and effective treatment of SHPT in non-dialysis CKD patients Jan Kielstein, Germany
- 14.05 Decreasing pill burden in dialysis patients: advances in hyperphosphataemia treatment Maria Jesús Lloret, Spain
- 14.25 Key takeaways from the panel and close All/Smeeta Sinha, UK (Chair)



Click **HERE** or scan the QR code to register for ERA 2023 and to gain access to this session.

Lunch will be provided

Date of preparation: March 2023 MED-HQ-RAY-2300010 © 2023 Vifor Fresenius Medical Care Renal Pharma Ltd. All rights reserved



CSL Vifor